CClinicalTrials.gg
CompletedNCT05944614TOWERUpdated Jul 3, 2025

Towards Optimal Treatment of Marfan Syndrome

An observational study in Marfan Syndrome, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Completed at 4 sites in Netherlands. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
148
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether new magnetic resonance imaging techniques can be used as a biomarker of aortic disease severity in patients with Marfan syndrome.

02

Conditions studied

  • Marfan Syndrome

Keywords

  • Magnetic Resonance Imaging
  • Aortic disease
03

In context

Marfan Syndrome

71 studies on the registry are indexed under Marfan Syndrome; 16 are open to participants now.

This study's enrollment of 148 is above the median of 119 across 40 observational studies indexed under Marfan Syndrome.

Browse Marfan Syndrome studies →

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 512 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All Marfan syndrome patients age 18-50 with a known FBN1 mutation are eligeble for participation. Only patients who are unable to undergo an MRI examination are excluded.

Inclusion criteria

  • MFS patients with a known FBN1 mutation
  • Between 18-50 years of age

Exclusion criteria

Exclusion Criteria:

  • Contraindication for MR imaging
  • Mental retardation
  • Pregnancy, or planned pregnancy during study period

Additional exclusion criteria healthy controls:

- History of aorta disease

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
148 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Marfan Syndrome patients

    Marfan Syndrome patients age 18-50 with a pathological FBN1 mutation

    Other: Magnetic Resonance imaging (MRI) examination

  • Healthy volunteers

    Age and gender matched healthy control patients without a history of aortic disease.

    Other: Magnetic Resonance imaging (MRI) examination

Interventions

  • OtherMagnetic Resonance imaging (MRI) examination

    3D CINE and 4 dimensional (4D) flow MRI sequence

06

What researchers measure

Primary outcomes

  1. Difference in 3D aortic displacement in millimeters between Marfan patients (MFS) and healthy volunteers.

    aortic displacement in the thoracic aorta. normal values unknown, but single paper: Marfan patients range: 1.77 to 10.03 millimeters, volunteers 7.34 ± 1.69 millimeters. lower is worse.

    Time frame: Baseline

  2. Difference in pulse wave velocity, in meters per second between Marfan patients and healthy volunteers.

    pulse wave velocity expressed in m/s in the thoracic aorta, normal values age dependent: but range +/- 4 - 30 m/s, higher is worse

    Time frame: Baseline

  3. Difference in oscillatory shear index (dimensionless) expressed in m/s between Marfan patients and healthy volunteers

    oscillatory shear index (dimensionless) in the thoracic aorta, range between 0 - 0.5 (No normal values defined), higher is worse

    Time frame: Baseline

  4. Change in aortic displacement expressed in millimeters , between MFS patient aortas prior to compared to after PEARS procedure or conventional aortic surgery.

    aortic displacement expressed in millimeters in the thoracic aorta. Pre-post change unknown, however operated 3.60 +/- 1.0 millimeter versus native aorta 7.01 +/- 3.09 millimeters. Lower is worse

    Time frame: Change from baseline to 6 months after surgery

  5. Change in aortic pulse wave velocity (meters/second), between MFS patient aortas prior to compared to after PEARS procedure or conventional aortic surgery.

    pulse wave velocity in the thoracic aorta expressed in meters/second. Higher is worse. normal values for change unknown.

    Time frame: Change from baseline to 6 months after surgery

  6. Change in oscillatory shear index (dimensionless) between MFS patient aortas prior to compared to after PEARS procedure or conventional aortic surgery.

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse range between 0 -5.

    Time frame: Change from baseline to 6 months after surgery

Secondary outcomes

  1. Difference in 3D aortic displacement expressed in mm between Marfan patients with and without a native aorta

    aortic displacement in the thoracic aorta, lower is worse. operated 3.60 +/- 1.0 millimeter versus native aorta 7.01 +/- 3.09 millimeters

    Time frame: Baseline

  2. Difference in 3D aortic displacement expressed in mm between Marfan patients with aortic root diameter >4.5cm versus <4.5 cm

    aortic displacement in the thoracic aorta, lower is worse. Normal values unknown.

    Time frame: Baseline

  3. Difference in 3D aortic displacement expressed in mm between Marfan patients with a haploinsufficient fibrillin 1 mutation versus dominant negative mutation

    aortic displacement in the thoracic aorta. Lower is worse. Normal values unknown.

    Time frame: Baseline

  4. Difference in 3D aortic displacement expressed in mm between male versus female Marfan patients

    aortic displacement in the thoracic aorta,Lower is worse. Normal values unknown.

    Time frame: Baseline

  5. Difference in 3D aortic displacement expressed in mm between Marfan patients based on antihypertensive medication used

    aortic displacement in the thoracic aorta, Lower is worse. Normal values unknown.

    Time frame: Baseline

  6. Difference in pulse wave velocity, expressed in meters per second between Marfan patients with and without a native aorta

    pulse wave velocity expressed in m/s in the thoracic aorta, Lower is worse. Normal values unknown. Single study in general aneurysm population: pre surgery: 18.0 +/-4.0 meters per second post surgery 20.6 +/- 6.0 meters per second. higher is worse

    Time frame: Baseline

  7. Difference in pulse wave velocity, expressed in m/s between Marfan patients with an aortic root diameter >4.5 cm versus <4.5 cm

    pulse wave velocity expressed in m/s in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  8. Difference in pulse wave velocity, expressed in m/s between Marfan patients with a haploinsufficient fibrillin-1 mutation versus a dominant negative mutation

    pulse wave velocity expressed in m/s in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  9. Difference in pulse wave velocity, expressed in m/s between male and female Marfan patients

    pulse wave velocity expressed in m/s in the thoracic aorta Higher is worse. Normal values unknown.

    Time frame: Baseline

  10. Difference in pulse wave velocity, expressed in m/s between Marfan patients based on antihypertensive medication used

    pulse wave velocity expressed in m/s in the thoracic aorta

    Time frame: Baseline

  11. Difference in oscillatory shear index (dimensionless) expressed in m/s between Marfan patients with and without a native aorta

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  12. Difference in oscillatory shear index (dimensionless) expressed in m/s between Marfan patients with aortic root diameter >4.5cm versus <4.5 cm

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  13. Difference in oscillatory shear index (dimensionless) expressed in m/s between Marfan patients with a haploinsufficient fibrillin 1 mutation versus dominant negative mutation

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  14. Difference in oscillatory shear index (dimensionless) expressed in m/s between male versus female Marfan patients

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  15. Difference in oscillatory shear index (dimensionless) expressed in m/s between Marfan patients based on antihypertensive medication used

    oscillatory shear index (dimensionless) in the thoracic aorta. Higher is worse. Normal values unknown.

    Time frame: Baseline

  16. The correlation between regional wall shear stress and elastic fibre thickness in resected aorta tissue of MFS patients.

    Correlation of locally MRI measured wall shear stress and histologic findings in the thoracic aorta. Neither is worse. Normal values dependent on location of measurement, exploratory outcome. .

    Time frame: Baseline MRI with aortic surgery tissue

07

Study locations

4 sites
  • Radboud University Medical Center
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Leiden University Medical Center
    Leiden, North Holland 2333 ZA, Netherlands
  • Amsterdam UMC, location AMC
    Amsterdam, 1105 AZ, Netherlands
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05944614
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Netherlands Organisation for Scientific Research
Responsible party
Dr. Ir. Pim van Ooij (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Jul 13, 2023
Start date
Feb 23, 2023
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Last update
Jul 3, 2025

Study contacts

Pim Ooij, PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion